{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Parikh M"],"funding":["National Cancer Institute (NCI)","Pharmaceuticals Bayer"],"pagination":["1946-1951"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12580894"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["5(11)"],"pubmed_abstract":["<h4>Purpose</h4>The ataxia telangiectasia and Rad3-related kinase inhibitor elimusertib synergizes with cisplatin preclinically. We evaluated the clinical feasibility of combining elimusertib with cisplatin.<h4>Patients and methods</h4>Patients with advanced solid tumors who had received <300 mg/m2 of prior cisplatin, and for whom cisplatin-based treatment was deemed appropriate, were enrolled according to a standard 3 + 3 design, starting elimusertib at 20 mg orally twice daily on days 2 and 9, with cisplatin 60 mg/m2 intravenously on day 1 of a 21-day cycle. Primary objectives were the determination of the maximum tolerated dose and safety. Secondary objectives included the assessment of elimusertib pharmacokinetics and preliminary efficacy.<h4>Results</h4>Fifteen patients were enrolled."],"journal":["Cancer research communications"],"pubmed_title":["The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404)."],"pmcid":["PMC12580894"],"funding_grant_id":["R50CA211241","P30CA047904","P30CA093373","UM1CA186717","U24CA247643"],"pubmed_authors":["Ruel C","Tam K","Danilov AV","Frankel P","Lara PN","Takebe N","Parikh M","Bedard PL","Holleran JL","Beumer JH","Gore SD","Noonan AM","Newman EM","Yang Y","Uboha NV","Wisinski KB","Yin M","Mittra A"],"additional_accession":[]},"is_claimable":false,"name":"The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404).","description":"<h4>Purpose</h4>The ataxia telangiectasia and Rad3-related kinase inhibitor elimusertib synergizes with cisplatin preclinically. We evaluated the clinical feasibility of combining elimusertib with cisplatin.<h4>Patients and methods</h4>Patients with advanced solid tumors who had received <300 mg/m2 of prior cisplatin, and for whom cisplatin-based treatment was deemed appropriate, were enrolled according to a standard 3 + 3 design, starting elimusertib at 20 mg orally twice daily on days 2 and 9, with cisplatin 60 mg/m2 intravenously on day 1 of a 21-day cycle. Primary objectives were the determination of the maximum tolerated dose and safety. Secondary objectives included the assessment of elimusertib pharmacokinetics and preliminary efficacy.<h4>Results</h4>Fifteen patients were enrolled.","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Nov","modification":"2026-06-05T10:45:18.557Z","creation":"2026-05-16T03:08:28.965Z"},"accession":"S-EPMC12580894","cross_references":{"pubmed":["41104717"],"doi":["10.1158/2767-9764.CRC-25-0305"]}}